Brenus annouces its international scientific committee.

LYON, (FRANCE), June 7th, 2023, – Following the American Society of Clinical Oncology’s, Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow”, the company highlighted its international scientific committee.   View PDF

ASCO annual meeting 2023 (HCL, Inovotion, Explicyte, IRCM, CGFL)

Benoit You, Corinne Tortorelli, Yan WANG, Arnaud Peyronnier, Alban Bessede, Céline Gongora, Benoit Pinteur, Lionel Chalus, George Alzeeb, Paul Bravetti, François Ghiringhelli; Abstract  e14661: Efficacy of STC-1010, a new allogenic cancer vaccine in colorectal cancer models. J Clin Oncol 41, 2023 (suppl 16; abstr e14661) 10.1200/JCO.2023.41.16_suppl.e14661   See PDF Abstract

Poster AACR Annual meeting 2023 (Explicyte, Institut Bergonié)

Alban Bessede, George Alzeeb, Corinne Tortorelli, Jean-Philippe Guegan, Christophe Rey, Lionel Chalus, Benoit Pinteur, Paul Bravetti, Antoine Italiano; Abstract LB224: STC-1010 a new therapeutic vaccine promotes tumor cell death. Cancer Res 15 April 2023; 83 (8_Supplement): LB224. https://doi.org/10.1158/1538-7445.AM2023-LB224   see PDF poster

Poster AACR Annual meeting 2023 (Inovotion)

Yan Wang, Arnaud Peyronnier, Benoit Pinteur, Lionel Chalus, Corinne Tortorelli, Paul Bravetti, Jean Viallet, François Ghiringhelli, Philippe Fornies; Abstract 6791: Inovative in vivo (in ovo) CAM model to predict efficacy and mode of action of a new antitumor vaccine stc-1010 on human colorectal adenocarcinoma. Cancer Res 1 April 2023; 83 (7_Supplement): 6791. https://doi.org/10.1158/1538-7445.AM2023-6791   See PDF poster

Poster SITC Annual Meeting 2022 (CLB, IRCM)

Tortorelli C, Gongora C, Mathe D, et al1179 Efficacy study of STC-1010 antitumor vaccine associated with standard chemotherapies on MC 38 syngeneic colon cancer tumor modelJournal for ImmunoTherapy of Cancer 2022;10 http://dx.doi.org/10.1136/jitc-2022-SITC2022.1179   See PDF poster

Poster SITC annual meeting 2022 (Inovotion)

Wang Y, Tortorelli C, Peyronnier A, et al 949 Inovative in vivo (in ovo) cam model to predict efficacy and mode of action of a new antitumor vaccine stc-1010 on human colorectal adenocarcinoma Journal for ImmunoTherapy of Cancer 2022;10: https://dx.doi.org/10.1136/jitc-2022-SITC2022.0949   See PDF poster

Poster AACR Annual Meeting 2022 (IRCM, Institut Bergonié)

Céline Gongora, Elsa Kress, Claudine Vermot-Desroches, Lionel Chalus, Jeremy Forget, Benoît Pinteur, Paul Bravetti, Charles Dumontet, Antoîne Italiano; Abstract 2051: Antitumor activity of a novel allogeneic colorectal cancer vaccine in C57BL/6 mice bearing MC38 anti-PD1 resistant colon carcinoma syngeneic model with TME. Cancer Res 15 June 2022; 82 (12_Supplement): 2051. https://doi.org/10.1158/1538-7445.AM2022-2051   See PDF poster

Poster AACR annual meeting 2022 (CGFL)

Corentin Richard, Sandy Chevrier, Lionel Chalus, Jeremy Forget, Benoît Pinteur, Paul Bravetti, Romain Boidot; Abstract 3566: Sensitizing potential of a novel stimulated and haptenized vaccine in immunotherapy resistant metastatic colorectal cancer. Cancer Res 15 June 2022; 82 (12_Supplement): 3566. https://doi.org/10.1158/1538-7445.AM2022-3566   See PDF Poster

AACR Virtual Special Conference 2021

  Céline Gongora, Jacqueline Taleb, Benoît Pinteur, Lionel Chalus, Fanny De Luca, Paul Bravetti, François Ghiringhelli; Abstract P003: Efficacy results of a novel vaccine composed of stimulated and haptenized tumors cells in Balbc mice grafted with murine colon adenocarcinoma CT26 cells. Cancer Immunol Res 1 January 2022; 10 (1_Supplement): P003. https://doi.org/10.1158/2326-6074.TUMIMM21-P003   See PDF Presentation

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with broad & higher quality range of tumor antigens